RECENT NEWS

Cepheid has announced that its Xpert HCV molecular test to detect hepatitis C at the point of care has been greenlit for the US market.

Moderna has announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines.

London pathology services provider Synnovis has recently issued a further update on its efforts to recover and restore services following the cyberattack at the start of June.

Lalita Ramakrishnan, Group Leader in the Medical Research Council’s Laboratory of Molecular Biology’s (LMB) Cell Biology Division and the University of Cambridge’s Molecular Immunity Unit (housed in the LMB), has been announced as the 2024 recipient of the Robert Koch Prize, in recognition of her pioneering research investigating the molecular mechanisms behind tuberculosis (TB).

Analysing nasal swabs taken during the pandemic, researchers at Yale School of Medicine suggest that the frequent presence of other viruses and bacteria may have helped to protect children from the worst effects of COVID-19 by boosting their immune systems.

The UK Health Security Agency (UKHSA), is continuing to work with partners to investigate the recent Shiga toxin-producing Escherichia coli (STEC) outbreak. It has confirmed further cases, including two deaths, but numbers of new cases are now decreasing.

A new study describes the outcome of a new approach to testing for Clostridioides difficile, guided by the principles of diagnostic stewardship and how it highlights the benefits of a clearly defined, evidence-based test-ordering process.

Bio-Rad Laboratories has launched Celselect Slides 2.0 to enhance rare cell and circulating tumour cell (CTC) capture. Compatible with Bio-Rad’s Genesis Cell Isolation System, the latest version of Celselect Slides enables the processing of greater volumes of liquid biopsy samples and offers the ability to capture and recover a greater number of CTCs for enumeration or use in downstream applications.

Proscia has established a new partner alliance – named Proscia Ready - to help laboratories grow their use of digital pathology through an increasingly comprehensive approach.

London-based pathology services partnership Synnovis has issued a further update following the recent cyberattack, confirming that patient information published online was stolen from its systems.

Bio-Rad Laboratories has launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. The company also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.

BIOHIT HealthCare is excited to announce an upcoming webinar, 'Current and future trends in inflammatory bowel disease (IBD) therapeutic drug monitoring (TDM)', which will take place on 3 July at 12:30-1:30pm BST.

A low-cost CRISPR-based paper-strip test distinguishes between influenza types and can be reprogrammed to recognise different viruses including H5N1 bird influenza. A recently published paper describes the development of the new test that could allow more patients to find out which type of influenza they have and get the right treatment.

The Royal College of Pathologists (RCPath) has announced the winners of its Achievement Awards. Six RCPath Achievement Awards were presented this year, four 'Team' awards and two awards for in the new category of 'Sustainability'.

Following five popular meetings, Cardiac Marker Dialogues is pleased to be back with an exciting programme for a sixth meeting in Glasgow in September 2024.

Roche has launched new analytical units, cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories.

NHS trusts are determined to do everything they can to help health services to be even more productive but need support from government and national bodies to unlock their full potential for improvement, a new report from NHS Providers says.

Bio-Rad Laboratories has announced the launch of the ddSEQ Single-Cell 3' RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.

Roche has announced the launch of the first clinically approved highly sensitive in situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. The test is designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection.

Registration is open now for The Power to Disrupt - Clinical Diagnostics Expo UK, the ninth face-to-face event provided by Thornhill Healthcare Events in partnership with POCTInnovators.com. Taking place in London during September, Pathology in Practice will be supporting the event with a special supplement.